OSTEOPORE LIMITED — Board/Management Information 2019

Dec 3, 2019

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

Former President & CEO of Cochlear (ASX: COH) joins Osteopore as Board Advisor

Highlights

• Former President and CEO of Cochlear, Jack O’Mahony, to join Osteopore as Board Advisor.

• Mr O’Mahony will work with Osteopore’s executive management team on strategic business development and assist in driving market penetration.

• Mr O’Mahony has agreed to an equity based remuneration package to align with the creation of shareholder value. His engagement will last 12 months with an option to extend.

4 December 2019: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, specifically engineered to facilitate natural bone healing, is pleased to announce that Mr Jack O’Mahony will join the Company as Board Advisor from 4 December 2019.

Mr O’Mahony will advise the Board and work with the Company’s CEO, Goh Khoon Seng, to assist with strategic business development and market penetration requirements as Osteopore seeks to establish new distribution agreements and increase revenue from its products. Mr O’Mahony has agreed to an equity-based remuneration structure to provide ongoing incentives towards building long term value for Osteopore shareholders.

Mr O’Mahony will bring over four decades of global medical device experience to Osteopore, and was previously President and CEO of Cochlear Ltd, one of Australia’s most valuable medical device companies. Having implemented growth strategies and infrastructure improvements as CEO of Cochlear, his tenure was marked with rapid international growth and achievement of record results. Prior to his role with Cochlear, Mr O’Mahony held roles as President Asia Pacific of Synthes prior to its sale to Johnson & Johnson for USD$22.3 billion, President of Howmedica (a division of Pfizer) and International President of Stryker Corp based in Europe. More recently Mr O’Mahony has been President, International Division of Signature Orthopeadics, an Australian medical device business.

Commenting on the appointment, Osteopore Chairman, Brett Sandercock said:

“We are delighted to have appointed an advisor to the Board with such deep and relevant experience, particularly in the medical device and orthopaedic sectors. Jack brings significant international experience and relationships to Osteopore that will further support Osteopore’s international expansion. Osteopore is well placed to deliver on the global growth strategy and we anticipate that we will all benefit from Jack’s significant experience.”

ENDS

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

For further information, media or investor enquiries, please contact:

Geoff Pocock

Osteopore Limited +61 4 1219 4373 geoff_pocock@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural. healthy bone tissue, significantly reducing postsurgery complications that are commonly associated with permanent bone implants.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com